Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome

<div>Comparison of metabolic/hepatic markers in the three PCOS groups (PCOS-C: patients who were insulin sensitive at baseline; PCOS-PIR: patients with IR at baseline and after treatment; PCOS-exIR: initially insulin resistant patients whose IR dissolved after treatment). Data are presented as percent changes (between baseline and after treatment) of prevalence and were analyzed using Chi²-tests.</div>

International Journal of Endocrinology

fig2

Figure 2

Figure 2: Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome 